Tel: 91 22 43031000, Fax 91 22 43034662

Sr. No.		Quarter	Year ended	
	Particulars	December 31, 2021 Unaudited	December 31, 2020 Unaudited	March 31, 2021 Audited
	WOLD AND AND AND AND AND AND AND AND AND AN			
1	Total Income from Operations	4,846.78	4,983.91	19,145.81
2	Net Profit / (loss) before exceptional items and tax	97.58	212.12	(437.77)
3	Net Profit / (Loss) before tax (after exceptional items)	97.58	307.60	(311.43)
4	Net Profit/ (Loss) for the period after tax (after exceptional items)	(106.91)	80.08	(532.30)
5	Total Comprehensive Income for the period	91.34	431.55	(131.71)
6	Paid-up Equity Share Capital	Processor	6300000000	263.03
7	Earnings Per Share (Face value of ₹ 10 each)	0.0778.003		8/48/36420
	(a) Basic (₹)	(4.07)	3.04	(20.24)
	(b) Diluted (₹)	(4.07)	3.04	(20.24)
	(Not annualised for quarter)	(6) (8)		105G (

		Quarter	Year ended	
Sr. No.	Particulars	December 31, 2021 Unaudited	December 31, 2020 Unaudited	March 31, 2021 Audited
1	Total Income from Operations	320.21	468.50	1,689.15
2	Net Profit / (loss) before exceptional items and tax	(192.49)	(194.06)	(465.08)
3	Net Profit / (Loss) before tax (after exceptional items)	(192.49)	37.91	(111.52)
4	Net Profit/ (Loss) for the period after tax (after exceptional items)	(193.27)	60.01	(19.08)
5	Total Comprehensive Income for the period	(193.27)	60.01	(18.87)
6	Paid up Equity Share Capital	10 Branch (1800 Fe)	55.54.66@3607.1	263.03
7	Reserves (excluding Revaluation Reserve)			10,112.55
8	Security Premium Account			8,825.09
9	Net worth			9,724.67
10	Outstanding Debt			3,808.09
11	Debt Equity Ratio	0.38	0.55	0.37
12	Earnings Per Share (Face value of ₹ 10 each)		HOSOEV	195987196
1000	(a) Basic (₹)	(7.35)	2.28	(0.73)
	(b) Diluted (₹)	(7.35)	2.28	(0.73)
	(Not annualised for quarter)		POSTURE	190,001,000
13	Capital Redemption Reserve	130.03	130.03	130.03
14	Debenture Redemption Reserve	212.98	212.98	212.98
15	Debt Service Coverage Ratio	(0.01)	0.03	0.30
16	Interest Service Coverage Ratio	(0.29)	0.95	2.05

D. The above is an extract of the detailed format of the financial results for the quarter ended December 31, 2021 drawn up

both on a Standalone and Consolidated basis, filed with Stock Exchanges on February 12, 2022 under Regulation 33 and

Regulation 52 read with regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The full format of the Financial Results (Standalone and Consolidated) for the guarter ended December 31, 2021 are

available on the Company's website, www.rinfra.com and on the website of the Stock Exchanges, www.bseindia.com and

Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013.

www.nseindia.com.

Date: February 12, 2022

Place: Mumbai

Registered Office: - 62B, Braunfeld Row, 1st Floor, Kolkata - 700 027

HINDCON CHEMICALS LIMITED CIN :- L24117WB1998PLC087800

Email id :- contactus@hindcon.com , Website :- www.hindcon.com

EXTRACT OF THE UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2021

-	Particulars				(Rs. in Lakhs Consolidated Results		
SI No.		Quarter ended on 31/12/2021		Corresponding 3 months ended in the Previous Year 31/12/2020 (Unaudited)	Quarter ended on 31/12/2021 (Unaudited)		Corresponding 3 months ended in the Previous Year 31/12/2020 (Unaudited)
		(Unaudited)					
1	Total income from operations (net)	1,692.04	4,358.36	1,296.52	1,698.51	4,627.69	1,299.41
2	Net Profit for the period (Before Tax and Exceptional items)	157.69	471.07	163.17	163.42	452.28	165.17
3	Net Profit/(Losses) for the period before tax (After Exceptional items)	157.69	471.07	163.17	163.42	452.28	165.17
4	Total Comprehensive Income for the period (Comprising Profit for the period after tax and Other Comprehensive Income after Tax)	134.69	460.05	181.46	127.88	432.17	192.58
5	Paid up Equity Share Capital (Face Value ₹10/- each)	1,023.81	1,023.81	1,023.81	767.20	767.20	767.20
6	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the Previous Year						
7	Basic & Diluted Earnings Per Share (Face Value ₹10/- each) (not Annualised)	1.10	3.48	1.19	1.39	3.98	1.61

Notes:

Place: Kolkata

Date: February 12, 2022.

- The above is an extract of the detailed format of Quarterly Unaudited Financial Results filed with the National Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results is available on the company's Website https://www.hindcon.com) and National Stock Exchange website - (www.nseindia.com).
- The Company has prepared the Consolidated Financial Statement on annual basis and the Consolidated financial figures include subsidary of the Company viz Hindcon Solutions Pvt Ltd.
- The Statutory Auditors have provided un-modified report on Unaudited Financial Results (Standalone & Consolidate) for quarter & nine months ended on 31.12.2021.
- The previous period figures have been regrouped/rearranged wherever necessary, to confirm to the current period figures.

For and on behalf of the Board Hindcon Chemicals Limited

(Sanjay Goenka) Chairman & Managing Director DIN - 00848190 SUNDAY, FEBRUARY 13, 2022 20

FE SUNDAY

WWW.FINANCIALEXPRESS.COM

UNITED CREDIT LIMITED

CIN: L65993WB1970PLC027781 Regd. Office: 27B, Camac Street (8th Floor), Kolkata - 700016 Ph.No. (033) 2287-9359/9360, Fax No. (033) 2287-2047 Email: unitedcreditltd@gmail.com, Website: www.unitedcreditltd.com EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2021

Quarter ended	Nine Months	Quarter
31/12/2021		ended 31/12/2020 Unaudited
55.93	176.12	66.41
16.99	60.41	27.03
16.99	60.41	27.03
19.58	49.08	19.99
19.58	49.08	19.99
549.30	549.30	549.30
0.37	0.92	0.38
0.37	0.92	0.38
	Unaudited 55.93 16.99 16.99 19.58 19.58	Unaudited Unaudited 55.93 176.12 16.99 60.41 16.99 60.41 19.58 49.08 19.58 49.08 549.30 549.30

I) The above is an extract of the detailed format of unaudited Financial Results for the Quarter and Nine Months ended 31.12.2021 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

ii) The full format of the Quarterly and Nine Months Financial Results are available on the websites of the Stock Exchanges at www.bseindia.com, www.cse-india.com and also on the Company's website at www.unitedcreditltd.com.

By ORDER OF THE BOARD (A. K. DABRIWALA) Chairman & Managing Director DIN: 00024498

Place: Kolkata Dated: 11th February, 2022

glenmark

GLENMARK PHARMACEUTICALS LIMITED

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mahalaxmi, Mumbai - 400 026. Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri (East), Mumbai - 400 099.

Tel No.: +91-22-4018 9999 Fax No.: +91-22-4018 9986

Email: complianceofficer@glenmarkpharma.com **Website:** www.glenmarkpharma.com CIN: L24299MH1977PLC019982

Statement of unaudited financial results for the quarter and nine months ended 31 December, 2021

(All amounts in million of Indian Rupees, unless otherwise stated) Standalone **Consolidated** Quarter ended Quarter ended Quarter ended Quarter ended Quarter ended Nine months Nine months Year ended Quarter ended Nine months Nine months Year ended **Particulars** ended ended ended ended 31/12/2020 31/12/2021 30/09/2021 31/12/2020 31/12/2021 31/03/2021 31/12/2021 30/09/2021 31/12/2021 31/12/2020 31/03/2021 31/12/2020 (Unaudited) (Unaudited) (Unaudited) (Audited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) Revenue from operations (a) Net sales 20,073.59 21,598.94 19,498.23 62,964.93 56,277.60 74,509.11 31,414.72 31,254.26 27,587.36 92,130.46 79,761.37 108,060.26 (b) Other operating income 256.95 209.72 226.55 595.44 898.05 1,170.22 319.42 220.21 280.27 727.10 1,078.92 1,379.03 80,840.29 109,439.29 Total revenue from operations 20,330.54 21,808.66 19,724.78 63,560.37 57,175.65 75,679.33 31,734.14 31,474.47 27,867.63 92,857.56 Other income 2,167.43 806.96 811.27 4,356.47 2,793.80 3,962.37 138.95 (130.72)150.90 594.72 417.23 502.16 79,641.70 Total income (I + II) 22,497.97 22,615.62 20,536.05 67,916.84 59,969.45 31,873.09 31,343.75 28,018.53 93,452.28 81,257.52 109,941.45 IV Expenses Cost of materials consumed 6,426.96 8,144.13 6,903.32 23,030.61 20,324.09 26,782.60 7,202.05 8,513.99 7,828.98 24,888.23 23,519.30 31,378.05 Purchases of stock-in-trade 1,255.58 1,180.91 897.98 3.838.10 2,319.22 3,159.55 2,744.00 2,862.73 2,532.35 8,792.64 5,726.96 7,502.69 Changes in inventories of finished goods, work-in-progress and stock-in-trade 49.98 (44.53)(197.44)46.72 (313.05)52.40 772.89 58.81 (1,247.66)(136.70)(1,641.78) (1,892.54)8,554.66 11,073.96 5,859.91 6,873.29 5,966.43 18,697.39 18,065.03 23,437.07 (d) Employee benefits expense 2,943.66 3,491.84 2,806.54 9,076.72 2,658.98 666.95 689.46 954.07 2,112.44 3,531.13 Finance costs 497.72 532.45 830.41 1,620.31 2,033.91 2,697.79 1,189.30 1,151.98 3,551.92 3,324.85 4,435.54 Depreciation, amortisation and impairment expense 407.98 396.83 412.12 1,179.22 1,138.15 1,508.15 1,231.90 8,223.77 7,263.96 7,486.81 22,047.01 19,561.25 (g) Other expenses 4,549.54 4,441.25 4,012.02 12,301.86 10,947.38 15,707.41 28,170.21 60,943.05 26,658.87 27,494.14 24,672.96 79,952.93 71,253.40 Total expenses (IV) 16,131.42 18,142.88 15,664.95 51,093.54 45,004.36 96,562.15 Profit/(loss) before exceptional items and tax (III - IV) 6,366.55 4,472.74 4.871.10 16,823.30 14,965.09 18,698.65 5,214.22 3,849.61 3,345.57 13,499.35 10,004.12 13.379.30 Exceptional items loss/(gain) (Refer note 5) (4,303.33)(459.02)(4,303.33)(738.92)(738.92)1,783.80 (134.15)1,783.80 (445.45) (445.45)Profit/(loss) before tax (V - VI) 6.366.55 8,776.07 5,330.12 21,126.63 15,704.01 19,437.57 3,430.42 3,849.61 3,479,72 11,715.55 10,449.57 13,824.75 VIII Tax expense : 1,406.48 1,250.76 932.03 3,708.13 2,746.89 3,436.18 1,631.30 1,232.01 1,212.43 4,309.30 3,902.49 4,981.40 Current tax (598.39)(130.45)Deferred tax (525.12)(17.27)(25.16)(503.44)(119.64)(493.08)(214.50)(804.58)(815.06) (857.53)Profit/(loss) for the period (VII - VIII) 5,485.19 7,542.58 4,423.25 17,921.94 13,076.76 16,494.47 2,397.51 2,748.05 2,481.79 8,210.83 7,362.14 9,700.88 Profit/(loss) for the period attributable to: Non-controlling interests 178.49 171.45 0.83 349.57 1.73 0.50 7,542.58 5,485.19 4,423.25 17,921.94 13,076.76 16,494.47 2,219.02 2,576.60 2,480.96 7,861.26 7,360.41 9,700.38 Owners of the Company Other comprehensive income (67.36)11.59 (21.48)15.76 32.33 17.28 (0.51)(24.49) (138.03) 51.79 A (i) Items that will not be reclassified to profit or loss 5.11 16.06 (5.50)(5.62)(7.49)(4.99)(0.58)(7.47)(ii) Income tax relating to items that will not be reclassified to profit or loss (4.77)8.23 (1.79)15.16 1.65 14.76 82.22 (532.39)1,125.91 525.78 1,094.38 719.81 B (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss (10.88)5.44 (77.86)(72.76)121.04 102.68 5,492.01 7,529.33 4,426.57 17,932.20 13,087.20 16,519.31 Total comprehensive income 2,481.14 2,168.90 3,528.75 8,641.01 8,454.29 10,567.69 XII Total comprehensive income attributable to: 349.73 Non-controlling interests 178.52 171.58 0.83 1.73 0.50 5,492.01 2,302.62 1,997.32 3,527.92 8,291.28 8,452.56 Owners of the Company 7,529.33 4,426.57 17,932.20 13,087.20 16,519.31 10,567.19 Paid up Equity Share Capital, Equity Shares of Rs. 1/- each 282.17 282.17 282.17 282.17 282.17 282.17 282.17 282.17 282.17 282.17 282.17 282.17 147,812.89 70,364.10 XIV Other equity XVEarning per share (EPS) (of Re 1/- each) (not annualised)* Basic EPS (in Rupees) 19.44 26.73 15.68 63.52 46.34 58.46 7.86 9.13 8.80 27.86 26.09 34.38 7.86 8.80 27.86 26.09 34.38 Diluted EPS (in Rupees) 19.44 26.73 15.68 63.52 46.34 58.46 9.13

* except for the year ended 31 March

1 The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

- The above results were reviewed by the Audit Committee at its meeting held on 10 February 2022 and approved by the Board of Directors at their meetings held on 11 February, 2022.
- The results for the quarter and Nine months ended 31 December, 2021 presented were subjected to a "Limited Review" by statutory auditors of the Company who have issued an unmodified report on the said results.
- The date of implementation of the Code on Wages 2019 and the Code on Social Security, 2020 is yet to be notified by the Government. The Company will assess the impact of these Codes and give effect in the financial results when the Rules/Schemes thereunder are notified.

Exceptional item of Rs. 1,783.80 in consolidated result for the quarter and nine months ended 31 December 2021 comprises of impairment of shares as part of its Initial Public Offering (IPO) and Offer for Sale (OFS). The company offered 6.3 million equity shares of Rs 2 each through OFS and resulted in a gain of Rs 4,303.33 (net of related expenses and cost of equity shares) and recorded as an exceptional item in the standalone financial results. Pursuant to requirements of Ind AS 110 para 23 and B96 such gain and tax thereon is directly recognised in equity in consolidated financial statements. Post the sale and IPO, the Company's holding in equity shares of GLS has reduced from 100% to 82.84 %.

Exceptional items in the standalone financial results for the quarter and nine months ended 31 December, 2020 of Rs. 459.02 and Rs. 445.45 respectively are on account of gain from transfer of intimate hygiene brand Vwash, Momat brands in certain geographies, sale of IP assets and reimbursement of onetime costs. The Chief Operating Decision Maker ("CODM") reviews the financial performance at pharmaceutical ingredient components, which are interlinked and inter-dependent, therefore, the Company has only one reportable segment,

- As at 31 December, 2021, pursuant to Employee Stock Options Scheme 2016, 404,247 options were outstanding, which upon exercise are convertible into equivalent number of equity shares.
 - The list of subsidiaries as of 31 December 2021 is provided in Annexure A.
- The Group continues to closely monitor the impact of the COVID-19 pandemic on all aspects of its business, including how it has impacted and how it will impact its customers, employees, vendors and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of goodwill, investments, intangible assets, inventory, based on the information available to date, both internal and external, while preparing the financial results for the quarter and Nine months ended 31 December, 2021.
- 10 Diluted EPS has been computed considering the effect of conversion of ESOPs.
- 11 Previous period's figures have been re-grouped/re-classified to render them comparable with the figures of the current period.

Annexure A

List of entities included in the consolidated financial results for guarter and nine moths ended 31 December 2021

1 Glenmark Pharmaceuticals Europe Ltd., U.K. 2 Glenmark Pharmaceuticals (Europe) R&D Ltd., U.K. 2 Glenmark Pharmaceuticals S.R.O. 5 Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S. A.) 6 Glenmark Holding S.A. 7 Glenmark Pharmaceuticals S.R.L (liquidated with effect from 30 July 2020) 8 Glenmark Pharmaceuticals Inc. 10 Glenmark Farmaceuticals Ltda 12 Glenmark Generics S.A 13 Glenmark Pharmaceuticals Mexico, S.A. DE C.V. 14 Glenmark Pharmaceuticals Peru SAC 15 Glenmark Pharmaceuticals Colombia SAS, Colombi Philippines Inc. 23 Glenmark Pharmaceuticals (Nigeria) Ltd 24 Glenmark Pharmaceuticals (Australia) Pty Ltd 26 Glenmark Pharmaceuticals (Oligeria) Ltd 27 Glenmark Pharmaceuticals (Oligeria) Pty Ltd 27 Glenmark Pharmaceuticals (Oligeria) Pty Ltd 28 Glenmark Pharmaceuticals (Oligeria) Pty Ltd 29 Glenmark Phar Pharmaceuticals B.V. 30 Glenmark Arzneimittel Gmbh 31 Glenmark Pharmaceuticals Canada Inc. 32 Glenmark Pharmaceuticals Canada Inc. 32 Glenmark Pharmaceuticals Distribution s.r.o. 36 Glenmark Pharmaceuticals Nordic AB 37 Glenmark Ukraine LLC 38 Glenmark Pharmaceuticals Ecuador S.A. 39 Glenmark Pharmaceutics SA) (Formerly known as Glenmark Pharmaceutics SA) 41 Ichnos Sciences Inc., USA (w.e.f. 31 May, 2019) 42 Glenmark Life Sciences Limited 43 Glenmark Distribuidora De Medicamentos E Produtos Cosmeticos Ltda. (up to 23 December 2020)

For and on behalf of the Board of Directors

V.S. Mani **Executive Director & Global Chief Financial Officer**

S/d

financialexp.epap

Mumbai, 11 February, 2022